Tg Therapeutics, Inc.NASDAQ: TGTX

TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis

· Issued by Tg Therapeutics, Inc.
Watch Tg Therapeutics explain itTG Therapeutics, Inc. (TGTX) Q2 2026 Earnings Call · Replay · Aug 3

The ULTIMATE I & II Phase 3 trials both have met their primary endpoint with ublituximab treatment demonstrating a statistically significant reduction in annualized relapse rate (ARR) over a 96-week period (p